Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 969342, 11 pages
http://dx.doi.org/10.1155/2014/969342
Research Article

Xanthoceraside Ameliorates Mitochondrial Dysfunction Contributing to the Improvement of Learning and Memory Impairment in Mice with Intracerebroventricular Injection of A 1-42

Department of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China

Received 13 December 2013; Revised 4 April 2014; Accepted 18 April 2014; Published 25 May 2014

Academic Editor: Jing Yu Yang

Copyright © 2014 Xue-Fei Ji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Devi and M. Ohno, “Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice,” Neurobiology of Disease, vol. 45, no. 1, pp. 417–424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Skaper, “Alzheimer's disease and amyloid: culprit or coincidence?” Neurobiology, vol. 102, pp. 277–301, 2012. View at Google Scholar
  3. S. Nakamura, N. Murayama, T. Noshita, H. Annoura, and T. Ohno, “Progressive brain dysfunction following intracerebroventricular infusion of beta1-42-amyloid peptide,” Brain Research, vol. 912, no. 2, pp. 128–136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Dragicevic, N. Copes, G. O'Neal-Moffitt et al., “Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling,” Journal of Pineal Research, vol. 51, no. 1, pp. 75–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Tomiyama, S. Matsuyama, H. Iso et al., “A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo,” Journal of Neuroscience, vol. 30, no. 14, pp. 4845–4856, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. M. LaFerla, K. N. Green, and S. Oddo, “Intracellular amyloid-β in Alzheimer's disease,” Nature Reviews Neuroscience, vol. 8, no. 7, pp. 499–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Tillement, L. Lecanu, and V. Papadopoulos, “Alzheimer's disease: effects of β-amyloid on mitochondria,” Mitochondrion, vol. 11, no. 1, pp. 13–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Dragicevic, M. Mamcarz, Y. Zhu et al., “Mitochondrial amyloid-β levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice,” Journal of Alzheimer's Disease, vol. 20, no. 2, pp. S535–S550, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. H. Reddy, R. Tripathi, Q. Troung et al., “Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1822, no. 5, pp. 639–649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Eckert, S. Hauptmann, I. Scherping et al., “Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice,” Neurodegenerative Diseases, vol. 5, no. 3-4, pp. 157–159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. S. Sohal, D. Toroser, C. Brégère, R. J. Mockett, and W. C. Orr, “Age-related decrease in expression of mitochondrial DNA encoded subunits of cytochrome c oxidase in Drosophila melanogaster,” Mechanisms of Ageing and Development, vol. 129, no. 9, pp. 558–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Mancuso, F. Coppedè, L. Murri, and G. Siciliano, “Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality?” Antioxidants and Redox Signaling, vol. 9, no. 10, pp. 1631–1646, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Maruszak and C. Zekanowski, “Mitochondrial dysfunction and Alzheimer's disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 2, pp. 320–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Fukui, F. Diaz, S. Garcia, and C. T. Moraes, “Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 35, pp. 14163–14168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Pickrell, H. Fukui, and C. T. Moraes, “The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 5, pp. 453–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Du, L. Guo, W. Zhang, M. Rydzewska, and S. Yan, “Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model,” Neurobiology of Aging, vol. 32, no. 3, pp. 398–406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Mao and P. H. Reddy, “Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1812, no. 11, pp. 1359–1370, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. P. J. Crouch, S.-M. E. Harding, A. R. White, J. Camakaris, A. I. Bush, and C. L. Masters, “Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 2, pp. 181–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Lu, T. Mamiya, L. Lu et al., “Xanthoceraside attenuates amyloid β peptide 25–35-induced learning and memory impairments in mice,” Psychopharmacology, vol. 219, no. 1, pp. 181–190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. T.-Y. Chi, L.-H. Wang, C. Qu et al., “Protective effects of xanthoceraside on learning and memory impairment induced by Aβ25–35 in mice,” Journal of Asian Natural Products Research, vol. 11, no. 12, pp. 1019–1027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Paxinos and K. B. J. Franklin, The Mouse Brain in Stereotaxic Coordinates, Gulf Professional Publishing, 2004.
  22. J. H. Jhoo, H.-C. Kim, T. Nabeshima et al., “β-Amyloid (1–42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex,” Behavioural Brain Research, vol. 155, no. 2, pp. 185–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J.-J. Yan, D.-H. Kim, Y.-S. Moon et al., “Protection against β-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 28, no. 1, pp. 25–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Liu, L. Zou, Q. Jiao et al., “Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats,” Neuroscience Letters, vol. 543, pp. 115–120, 2013. View at Google Scholar
  25. S. Hauptmann, I. Scherping, S. Dröse et al., “Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice,” Neurobiology of Aging, vol. 30, no. 10, pp. 1574–1586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. N. R. Sims, “Rapid isolation of metabolically active mitochondria from rat brain and subregions using percoll density gradient centrifugation,” Journal of Neurochemistry, vol. 55, no. 2, pp. 698–707, 1990. View at Google Scholar · View at Scopus
  27. M. F. Anderson and N. R. Sims, “Improved recovery of highly enriched mitochondrial fractions from small brain tissue samples,” Brain Research Protocols, vol. 5, no. 1, pp. 95–101, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. N. R. Sims and M. F. Anderson, “Isolation of mitochondria from rat brain using Percoll density gradient centrifugation,” Nature Protocols, vol. 3, no. 7, pp. 1228–1239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Hansson, R. Månsson, S. Morota et al., “Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition,” Free Radical Biology and Medicine, vol. 45, no. 3, pp. 284–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Yang, Q. Shi, D. J. Ho et al., “Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins,” Neurobiology of Disease, vol. 36, no. 2, pp. 320–330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Benilova, E. Karran, and B. De Strooper, “The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes,” Nature Neuroscience, vol. 15, no. 3, pp. 349–357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Findeis, “The role of amyloid β peptide 42 in Alzheimer's disease,” Pharmacology and Therapeutics, vol. 116, no. 2, pp. 266–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Chambon, N. Wegener, A. Gravius, and W. Danysz, “Behavioural and cellular effects of exogenous amyloid-β peptides in rodents,” Behavioural Brain Research, vol. 225, no. 2, pp. 623–641, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Wang, H. Yan, and X.-C. Tang, “Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine,” Acta Pharmacologica Sinica, vol. 27, no. 1, pp. 1–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Y. Zhang and X. C. Tang, “Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease,” Trends in Pharmacological Sciences, vol. 27, no. 12, pp. 619–625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Y. Zhang, H. Yan, and X. C. Tang, “Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase,” Cellular and Molecular Neurobiology, vol. 28, no. 2, pp. 173–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Wang, H. Y. Zhang, and X. C. Tang, “Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by β-amyloid protein-(1–40) in rat,” European Journal of Pharmacology, vol. 421, no. 3, pp. 149–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Gao and C. T. Xi, “Huperzine A attenuates mitochondrial dysfunction in β-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism,” Journal of Neuroscience Research, vol. 83, no. 6, pp. 1048–1057, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Gao, C. Y. Zheng, L. Yang, X. C. Tang, and H. Y. Zhang, “Huperzine A protects isolated rat brain mitochondria against β-amyloid peptide,” Free Radical Biology and Medicine, vol. 46, no. 11, pp. 1454–1462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Y. Chi, L. H. Wang, X. F. Ji, L. Shen, and L. B. Zou, “Protective effect of xanthoceraside against β-amyloid-induced neurotoxicity in neuroblastoma SH-SY5Y cells,” Journal of Asian Natural Products Research, vol. 15, no. 9, pp. 1013–1022, 2013. View at Google Scholar
  41. N. Exner, A. K. Lutz, C. Haass, and K. F. Winklhofer, “Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences,” The EMBO Journal, vol. 31, no. 14, pp. 3038–3062, 2012. View at Google Scholar
  42. Y. Shapovalov, D. Hoffman, D. Zuch, K. L. De Mesy Bentley, and R. A. Eliseev, “Mitochondrial dysfunction in cancer cells due to aberrant mitochondrial replication,” Journal of Biological Chemistry, vol. 286, no. 25, pp. 22331–22338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. W. Lustbader, M. Cirilli, C. Lin et al., “ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease,” Science, vol. 304, no. 5669, pp. 448–452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. I. Praceri, V. Rinnoci, S. Bagnoli, Y. Failli, and S. Sorbi, “Mitochondria and Alzheimer's disease,” Journal of the Neurological Sciences, vol. 322, no. 1-2, pp. 31–34, 2012. View at Google Scholar
  45. V. Chauhan and A. Chauhan, “Oxidative stress in Alzheimer's disease,” Pathophysiology, vol. 13, no. 3, pp. 195–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Adam-Vizi, “Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources,” Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1140–1149, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. P. H. Reddy, “Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease,” Experimental Neurology, vol. 218, no. 2, pp. 286–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Du and S. S. Yan, “Mitochondrial medicine for neurodegenerative diseases,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 5, pp. 560–572, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. K. Parks, T. S. Smith, P. A. Trimmer, J. P. Bennett Jr., and W. J. Davis Parker, “Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro,” Journal of Neurochemistry, vol. 76, no. 4, pp. 1050–1056, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Yao, R. W. Irwin, L. Zhao, J. Nilsen, R. T. Hamilton, and R. D. Brinton, “Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14670–14675, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. X. Wang, B. Su, L. Zheng, G. Perry, M. A. Smith, and X. Zhu, “The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease,” Journal of Neurochemistry, vol. 109, no. 1, pp. 153–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. X. Wang, B. Su, S. L. Siedlak et al., “Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 49, pp. 19318–19323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Decker, K. Y. Lo, S. M. Unger, S. T. Ferreira, and M. A. Silverman, “Amyloid-β peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3β in primary cultured hippocampal neurons,” Journal of Neuroscience, vol. 30, no. 27, pp. 9166–9171, 2010. View at Publisher · View at Google Scholar · View at Scopus